%0 Journal Article
%A Aarsland, Dag
%A Sunde, Anita Lenora
%A Tovar-Rios, Diego A
%A Leuzy, Antoine
%A Fladby, Tormod
%A Zetterberg, Henrik
%A Blennow, Kaj
%A Tan, Kübra
%A De Santis, Giovanni
%A Yakoub, Yara
%A Arslan, Burak
%A Huber, Hanna
%A Pola, Ilaria
%A Grötschel, Lana
%A Di Molfetta, Guglielmo
%A Skjellegrind, Håvard K
%A Selbaek, Geir
%A Ashton, Nicholas J
%T Prevalence of Alzheimer's disease pathology in the community.
%J Nature
%V 650
%N 8100
%@ 0028-0836
%C London [u.a.]
%I Nature Publ. Group
%M DZNE-2026-00147
%P 182 - 186
%D 2026
%X The prevalence of Alzheimer's disease neuropathological changes (ADNCs), the leading cause of cognitive impairment, remains uncertain. Recent blood-based biomarkers enable scalable assessment of ADNCs1. Here we measured phosphorylated tau at threonine 217 in 11,486 plasma samples from a Norwegian population-based cohort of individuals over 57 years of age as a surrogate marker for ADNCs. The estimated prevalence of ADNCs increased with age, from less than 8
%K Humans
%K Alzheimer Disease: epidemiology
%K Alzheimer Disease: pathology
%K Alzheimer Disease: blood
%K Alzheimer Disease: diagnosis
%K Aged
%K Prevalence
%K Aged, 80 and over
%K Male
%K Female
%K tau Proteins: blood
%K tau Proteins: chemistry
%K Norway: epidemiology
%K Cognitive Dysfunction: epidemiology
%K Cognitive Dysfunction: blood
%K Cognitive Dysfunction: pathology
%K Middle Aged
%K Phosphorylation
%K Cohort Studies
%K Biomarkers: blood
%K Age Factors
%K tau Proteins (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41407852
%R 10.1038/s41586-025-09841-y
%U https://pub.dzne.de/record/285022